A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
NCT06873555 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2025-03-19
Summary
This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.
Conditions
Interventions
- DRUG
-
DC05F01
DC05F01 capsule
Sponsors & Collaborators
-
Heronova Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-11
- Primary Completion
- 2026-08-31
- Completion
- 2026-08-31
Countries
- China
Study Locations
More Related Trials
-
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
NCT01469793 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
NCT06560112 ·Status: RECRUITING ·Phase: PHASE2
-
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
NCT06279104 ·Status: RECRUITING
-
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
NCT06243185 ·Status: RECRUITING ·Phase: PHASE2
-
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
NCT04828616 ·Status: UNKNOWN ·Phase: PHASE2
-
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
NCT05551507 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
NCT06173037 ·Status: COMPLETED ·Phase: PHASE2
-
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer
NCT06990503 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)
NCT04678102 ·Status: UNKNOWN ·Phase: PHASE1
-
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
NCT00672295 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
NCT06682572 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Culture of Ovarian Cancer Organoids and Drug Screening
NCT04768270 ·Status: UNKNOWN
-
Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
NCT01611766 ·Status: UNKNOWN ·Phase: PHASE3
-
Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02627443 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
NCT01851746 ·Status: UNKNOWN
-
Exploratory Study on HER2 Detection Method and Positive Threshold for High-grade Serous Adenocarcinoma of the Ovary
NCT06883487 ·Status: RECRUITING
-
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
NCT05170594 ·Status: UNKNOWN ·Phase: PHASE2
-
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
NCT05044091 ·Status: UNKNOWN
-
Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer
NCT00189579 ·Status: TERMINATED ·Phase: PHASE2
-
Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02050009 ·Status: WITHDRAWN ·Phase: PHASE1
-
Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer
NCT05633199 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer
NCT06890858 ·Status: RECRUITING ·Phase: PHASE2
-
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
NCT06686030 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
NCT04217798 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
NCT03763123 ·Status: UNKNOWN ·Phase: PHASE1